RT Book, Section
A1 Papadakis, Maxine A.
A1 McPhee, Stephen J.
A1 Rabow, Michael W.
A1 McQuaid, Kenneth R.
SR Print(0)
ID 1193123649
T1 Mycotic Infections Year in Review
T2 Current Medical Diagnosis & Treatment 2023
YR 2023
FD 2023
PB McGraw-Hill Education
PP New York, NY
SN 9781264687343
LK accessmedicine.mhmedical.com/content.aspx?aid=1193123649
RD 2024/04/25
AB Oral  ibrexafungerp,  a  highly  bioavailable  glucan  synthase  inhibitor,  may  be  used  to  treat  vulvovaginal  candidiasis  from  any  disease-causing  Candida  strains,  including  azole-resistant  pathogens.